Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAFTOVI + MEKTOVI Specified Drug Use Survey in BRAF-mutant Colorectal Cancer
jRCT2011210012Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of encorafenib and binimetinib in colorectal cancer (CRC), sponsored by Ono Pharmaceutical. Primary endpoints: Safety - overall adverse drug reactions and infections, Safety - specified safety concerns and 3 more. Started Mar 2021; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2011210012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210012.